CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33(+) targets

Myelodysplastic syndromes (MDS) are stem cell disorders that can progress to acute myeloid leukemia. Although hematopoietic cell transplantation can be curative, additional therapies are needed for a disease that disproportionally afflicts the elderly. We tested the ability of a CD16xCD33 BiKE to in...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Gleason, Michelle K., Ross, Julie A., Warlick, Erica D., Lund, Troy C., Verneris, Michael R., Wiernik, Andres, Spellman, Stephen, Haagenson, Michael D., Lenvik, Alexander J., Litzow, Mark R., Epling-Burnette, Pearlie K., Blazar, Bruce R., Weiner, Louis M., Weisdorf, Daniel J., Vallera, Daniel A., Miller, Jeffrey S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2014
Teme:
Myeloid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4014844/
https://ncbi.nlm.nih.gov/pubmed/24652987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-10-533398
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items